Treating Hypersensitivity Disorders by Focusing on Specific Sodium Channels

An Empowered Patient Podcast at Medical and Pharma Insider hosted by Karen Jagoda



John Mulcahy PhD, President and CEO of SiteOne Therapeutics discussess the broadening of their pipeline from acute pain to hypersensitivity disorders like chronic cough and itching.


The approach is to inhibit voltage-gated subtype sodium channel Nav1.7, a genetically validated target for pain, which the pain signal in the peripheral nervous system before it gets to the spinal cord avoids some of the liabilities with existing pain medications including opioids.


SiteOne's lead candidate is now an intravenous analgesic showing proof of concept for the treatment of acute pain and itch.


Listen to Podcast


Podcast Transcript


Siteone Therapeutics Website